Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Making the Most of Biomarker Testing in NSCLC
Making the Most of Biomarker Testing in NSCLC
On the Frontlines of Non-Small Cell Lung Cancer
Making the Most of Biomarker Testing in NSCLC
Steve Jackson, PharmD; Angel Qin, MD
- Steve Jackson, PharmD
- Angel Qin, MD
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
MinuteCE®
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
MinuteCE®
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
MinuteCE®
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Biomarker Testing After Progression in HR+/HER2- mBC
Biomarker Testing After Progression in HR+/HER2- mBC
On the Frontlines of Metastatic Breast Cancer
Biomarker Testing After Progression in HR+/HER2- mBC
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
News
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
A.J. Gelderblom, MD, PhD
- A.J. Gelderblom, MD, PhD
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
CME/CE
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
Amer Zeidan, MBBS; Guillermo Garcia-Manero, MD
0.50 credits
- Amer Zeidan, MBBS
- Guillermo Garcia-Manero, MD
0.50 credits
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
CME/CE
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
0.50 credits
- Jennifer R. Brown, MD, PhD
0.50 credits

Medical News

Medical News
Postoperative Desmoid Risk in FAP by APC Variant and Family History
11/06/2026
Read more
Medical News
AI-Derived PSMA PET-CT Tumor Volume Linked to Mortality
11/06/2026
Read more
Medical News
Prostate MRI: PI-RADS Cutoffs Shift Cancer Detection Accuracy
11/06/2026
Read more
Medical News
Medicaid Coverage Linked to Lower Liver Transplant Listing Odds in HCC
11/05/2026
Read more

CME/CE

KRAS G12C Biology: Why Is This Mutation Different?
KRAS G12C Biology: Why Is This Mutation Different?
MinuteCE®
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
MinuteCE®
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
0.75 program credits
- Gerard A. Silvestri MD, MS
0.75 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits

Clinical Practice

Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
MinuteCE®
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Project Oncology®
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Alexandria May, PharmD, BCPS; Neil M. Iyengar, MD
- Alexandria May, PharmD, BCPS
- Neil M. Iyengar, MD
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
On the Frontlines of Metastatic Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS; Heather McArthur, MD, MPH, FASCO
- Alexandria May, PharmD, BCPS
- Heather McArthur, MD, MPH, FASCO
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Clinician's Roundtable
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Nicholas Pastis, MD
- Nicholas Pastis, MD

Programs

CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Project Oncology®
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Alexandria May, PharmD, BCPS; Tara Graff, DO, MS
- Alexandria May, PharmD, BCPS
- Tara Graff, DO, MS
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
MinuteCE®
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS